Global Hospital Acquired Infections Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Test (Traditional Diagnostic Test, Molecular Diagnostic Assay, Immunoassays, Mass Spectrometry), By Product (Reagents, Analyzers), By Infection Type (Urinary Tract Infections (UTIs), Surgical Site Infections, Respiratory Infections, and Others), By End-User (Hospitals, Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032

Industry: Healthcare

RELEASE DATE Dec 2023
REPORT ID SI3100
PAGES 200
REPORT FORMAT PathSoft

Global Hospital Acquired Infections Diagnostics Market Insights Forecasts to 2032

  • The Global Hospital Acquired Infections Diagnostics Market Size was valued at USD 4.09 Billion in 2022.
  • The Market is Growing at a CAGR of 6.6 % from 2022 to 2032
  • The Worldwide Hospital Acquired Infections Diagnostics Market Size is expected to reach USD 7.80 Billion by 2032
  • Asia-Pacific is expected to Grow the fastest during the forecast period

 

Global Hospital Acquired Infections Diagnostics Market

Get more details on this report -

Request Free Sample PDF

The Global Hospital Acquired Infections Diagnostics Market Size is anticipated to exceed USD 7.80 Billion By 2032, Growing at a CAGR of 6.6 % from 2022 to 2032.

 

Rising hospital-acquired infections diagnostics incidence as a result of increased hospital admissions, chronic disease development, and the emergence of antibiotic-resistant bacteria are major factors driving market revenue growth.

 

Market Overview

Hospital-acquired infection, also known as nosocomial infection, can occur in patients who are admitted to hospitals or healthcare facilities for various diseases. Infections can occur in a hospital, nursing home, rehabilitation facility, outpatient clinic, or other therapeutic setting. They can be acquired from an infected patient, the surrounding environment, or the facility's staff. A nosocomial infection or hospital-acquired infection is an infection or toxin that exists in a specific location, such as a hospital, and can be contacted by a patient who visits or is admitted to the hospital for any reason other than this infection. ICUs, or intensive care units, are the most common places where HAIs occur because doctors treat serious diseases there. Infections of the gastrointestinal tract, surgical sites, respiratory tract, bloodstream, urinary tract, bone and joint infections, and cardiovascular system are the most common. With the recent past incident increase in COVID-19 cases, there is a greater emphasis on personal hygiene, as well as an increase in the production of medical nonwovens and single-use products such as face masks and gloves.

 

Report Coverage

This research report categorizes the market for the global hospital-acquired infections diagnostics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the hospital-acquired infections diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the hospital-acquired infections diagnostics market.

 

Global Hospital Acquired Infections Diagnostics Market Report Coverage

Report CoverageDetails
Base Year:2022
Market Size in 2022:USD 4.09 Billion
Forecast Period:2022-2032
Forecast Period 2022-2032 CAGR:6.6 %
2032 Value Projection:USD 7.80 Billion
Historical Data for:2018-2021
No. of Pages:200
Tables, Charts & Figures:120
Segments covered:By Test, By Product, By Infection Type, By End-User, By Region and COVID-19 Impact Analysis.
Companies Covered: BIOMERIEUX, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, BD (Becton, Dickinson, and Company), Bioscience, Inc., QIAGEN, Thermo Fisher Scientific Inc., Meridian Bioscience, Inc., Hologic, Inc., ECOLAB, PFIZER INC., STERIS PLC and Other key vendors.
Pitfalls & Challenges:COVID-19 Empact, Challenge, Future, Growth, & Analysis

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

The increase in the prevalence of hospital-acquired infections, increased awareness about hospital-acquired infections, improved healthcare infrastructure, increased R&D spending, technological advancements, and increased government initiatives are driving the growth of the hospital-acquired infection diagnostics market share. Furthermore, the increasing use of molecular diagnostic methods such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAAT) is driving market revenue growth.

 

Restraining Factors

The lack of standardization in HAI (hospital-acquired infections) diagnostic tests is a major factor that may limit market revenue growth. Another factor that could hamper market revenue growth is the high cost of diagnostic tools and tests. Some healthcare facilities may be unable to afford HAI (hospital-acquired infections) diagnostic tests and equipment, limiting the range of testing and treatment options.

 

Market Segmentation

The Global Hospital Acquired Infections Diagnostics Market share is classified into test, product, infection type, and end user.

 

  • Immunoassays test is expected to grow fastest in the global hospital-acquired infections diagnostics market during the forecast period.      

Based on test, the hospital-acquired infections diagnostics market has been segmented into traditional diagnostic test, molecular diagnostic assay, immunoassays, mass spectrometry. Among these, the immunoassays test segment is expected to grow the fastest in the global hospital-acquired infections diagnostics market during the forecast period. Immunoassays are critical in diagnosing a variety of medical conditions, including hospital-acquired infections. Among the most commonly used immunodiagnostic tests in HAI diagnostics are enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), immunofluorescence assay (IFA), and serological testing.

 

  • The Reagents segment dominates in the global hospital-acquired infections diagnostics market during the forecast period.   

Based on the product, the global hospital-acquired infections diagnostics market is divided into reagents and analyzers. Among these, reagents segment dominates in the global hospital-acquired infections diagnostics market during the forecast period. The need for accurate and timely detection of infections in healthcare facilities drives the demand for reagents used in hospital acquired infections. Market participants are developing highly sensitive and specific infectious agents linked to HAIs. This enables accurate detection even at low concentrations, increasing the likelihood of early and reliable diagnosis. These reagents can be integrated into automated diagnostic systems, increasing efficiency while decreasing human error.

 

  • The surgical site infections segment is expected to grow at the highest pace in the global hospital-acquired infections diagnostics market during the anticipated period.   

Based on the infection type, the global hospital-acquired infections diagnostics market is divided into urinary tract infections (UTIs), surgical site infections, respiratory infections, and others. Among these, surgical site infections are expected to grow at the highest pace in the global hospital acquired Infections diagnostics market during the forecast period. Surgical site infections have become more common as surgical procedures and hospitals have expanded around the world. As a result, there is a greater need for improved HAI diagnostics for surgical site infections, such as blood culture tests, PCR testing, and immunoassays, which is driving revenue growth in this market.

 

  • The Hospitals dominate in the global hospital-acquired infections diagnostics market during the forecast period.   

Based on the end user, the global hospital-acquired infections diagnostics market is divided into hospitals, clinics, diagnostic centers, and others. Among these, hospitals dominate in the global hospital-acquired infections diagnostics market during the forecast period. Hospitals are contributing to the growth are an increase in awareness about hospital-acquired infections. With the recent past incident increase in COVID-19 cases, there is a greater emphasis on personal hygiene by hospitals. Hospitals have improved HAI diagnostics for surgical site infections, such as blood culture tests, PCR testing, and immunoassays, fueling revenue growth in this market.

 

Regional Segment Analysis of the Global Hospital-Acquired Infections Diagnostics Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global hospital-acquired infections diagnostics market over the predicted timeframe.

Global Hospital Acquired Infections Diagnostics Market

Get more details on this report -

Request Free Sample PDF

North America is projected to hold the largest share of the global hospital-acquired infections diagnostics market over the predicted timeframe. The growing demand for and adoption of sterilization and disinfection products and services is a result of consumers' increased emphasis on healthy lifestyles and disease prevention. The increase in the geriatric population in the coming years, as well as the subsequent rise in the prevalence of chronic diseases, the need for hospital-acquired infection control to reduce the prevalence of HAIs, and the implementation of favorable government initiatives and stringent sterilization and disinfection regulations, are all driving the hospital-acquired infection market in the region.

 

Asia-Pacific is expected to grow the fastest in the global hospital-acquired infections diagnostics market during the forecast period. The high growth rate can be attributed to the region's high geriatric population and rising disease incidence rate. Increasing demand for low-cost diagnostics and a growing population are two major factors driving regional market growth. The increasing prevalence of HAI in countries such as India and China is expected to fuel the industry shortly.

 

Competitive Analysis:

 

The report offers the appropriate analysis of the key organizations/companies involved within the global hospital-acquired infections diagnostics along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • BIOMÉRIEUX
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • BD (Becton, Dickinson, and Company)
  • Bioscience, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.
  • ECOLAB
  • PFIZER INC.
  • STERIS PLC

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

  • In October 2021, Thermo Fisher Scientific Inc. introduced the QMS Plasmid Screening Assay, which detects antibiotic-resistance genes in hospital-acquired infections. The assay detects antibiotic resistance genes quickly, accurately, and consistently, helping to reduce the spread of these infections and improve patient outcomes.

 

  • In February 2021, Danaher Corporation completed its acquisition of Aldevron, a biotechnology firm specializing in the production of plasmid DNA and other biologicals. The $9.6 billion acquisition aimed at expanding Danaher's product offerings in the biopharmaceutical market, including diagnostics for hospital-acquired infections.

 

This study forecasts revenue at global, regional, and country levels from 2020 to 2032. Spherical Insights has segmented the global hospital acquired Infections diagnostics market based on the below-mentioned segments: 

 

Global Hospital Acquired Infections Diagnostics Market, By Test

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay
  • Immunoassays
  • Mass Spectrometry

 

Global Hospital Acquired Infections Diagnostics Market, By Product

  • Reagents
  • Analyzers

 

Global Hospital Acquired Infections Diagnostics Market, By Infection Type

  • Urinary Tract Infections (UTIs)
  • Surgical Site Infections
  • Respiratory Infections
  • Others

 

Global Hospital Acquired Infections Diagnostics Market, By End User

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Others

 

Global Hospital Acquired Infections Diagnostics Market, By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies